Skip to content
Search

Latest Stories

People infected with monkeypox can isolate at home, says Health Security Agency

People infected with monkeypox can isolate at home if they remain well enough, whilst following measures to limit close contact with others, the UK's health security agency (UKHSA) said on Monday (May 30), part of guidance designed to curb the country's rise in cases of the viral illness.

More than 300 suspected and confirmed cases of monkeypox have been reported in May, outside of Africa where the virus is endemic. The usually mild illness spreads through close contact and can cause flu-like symptoms and pus-filled skin lesions.


An additional 71 cases of monkeypox have been identified in England, taking the total number of confirmed cases in the UK as a whole to 179 since early May.

Scientists are looking into what might explain the unusual surge of cases, given most are not linked to travel.

The UKHSA indicated community transmission was occurring in the UK and said infected people should avoid contact with others until their lesions have healed and the scabs have dried off.

Infected people can limit the risk of spread by using standard cleaning and disinfection methods, and washing their own clothing and bed linen with detergents in a washing machine, the agency advised.

In addition, infected people should abstain from sex as soon as symptoms appear, the agency said. While there is currently no available evidence of monkeypox spreading via genital excretions, it advised that people with the virus should use condoms for eight weeks after infection as a precaution.

The highest risk of transmission is through direct contact with someone with monkeypox - but the overall risk to the UK population remains low, said Ruth Milton, senior medical advisor and monkeypox strategic response director at UKHSA.

The agency, which is offering a vaccine to close contacts of cases, has procured more than 20,000 doses of a smallpox vaccine made by Bavarian Nordic.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less